Forescout Technologies has entered a strategic partnership with medical device security solution Medigate to help secure the Internet of Medical Things (IoMT), IoT, operational technology (OT) and IT network-connected devices.
The partnership enables Forescout to resell the Medigate Platform.
As part of the collaboration, the companies have developed an integration to combine Medigate’s in-depth IoMT visibility with Forescout’s enterprise device visibility.
Medigate allows info security, IT, biomedical and clinical engineering teams to detect, monitor and secure every medical device on the clinical network.
The platform’s medical device classification and information will enable Forescout to apply granular access control, segmentation and other compliance policies for clinical networks.
For a centralised device visibility and control platform, Forescout expects to extend these capabilities across all other connected devices in the health delivery organisation.
Forescout chief product and strategy officer Pedro Abreu said: “Connected medical devices represent a fast-growing threat attack vector and the lack of device manufacturer standardisation and interoperability has created a significant problem for clinical care network operations.
“The combination of Medigate’s deep knowledge of medical devices and the healthcare industry with Forescout’s breadth of device intelligence adds a new level of cohesive device insight, expertise and security for the healthcare industry.”
The joint offering will make use of passive technologies to analyse and classify all connected medical devices and IT assets on health delivery organisation networks, including unknown and hard-to-classify devices.
Furthermore, it will provide effective vulnerability management, anomaly and threat detection and risk scoring by allowing insights to support corporate security policies that protect biomedical devices.
Medigate co-founder and CEO Jonathan Langer said: “The Medigate and Forescout partnership and integration provide healthcare organisations with rich contextual visibility into their IT and clinical networks, as well as sophisticated network analysis to detect threats and implement clinically-driven policies.”
A coordinated sales and marketing strategy, also announced as part of the partnership, was designed to address customers’ IT, clinical technology and biomedical needs.